

SATURN: Effect of secukinumab in the treatment

Submission date 18/07/2016	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 21/07/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 23/06/2020	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Psoriatic arthritis (PsA) is a type of arthritis that usually develops in people with the skin condition psoriasis (a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales). PsA causes painful inflammation (swelling) and stiffness in the joints. In PsA, like in psoriasis alone, it is thought to be caused by the immune system mistakenly attacking healthy tissue (autoimmune disease). This study is being carried out to investigate the effects of a drug called secukinumab on patients with psoriatic arthritis. Secukinumab is medication which works by reducing the effects of chemical substances in the body that lead to inflammation (immunosuppressant). This will be done by investigating the effects on components of the blood, including white blood cells (which fight infection), vitamin D and cytokines (small proteins that help cells communicate with each other) in people with PsA and on the blood of healthy participants.

Who can participate?

Adults with PsA who have not previously had biologic therapy and healthy adults who are employed at University of Liverpool or Aintree University hospitals.

What does the study involve?

Eligible patients are registered into the study and receive four injections just below the skin (subcutaneous injections) of 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections of 150mg once a month for a total of 12 months, as well as standard treatment with normal disease-modifying antirheumatic drugs (DMARDs, a group of drugs used to treat arthritis by reducing inflammation and reducing damage to the joints). At the start of the study, and then after 3, 6, 9 and 12 months, participants have a sample of blood taken so that white blood cell, vitamin D and cytokine concentrations can be measured. The healthy participants provide a sample of blood at the same time points which is then tested for neutrophil (a type of white blood cell which help fight infection by ingesting microorganisms and releasing enzymes that kill the microorganisms) levels, which are then compared to the results of the participants with PsA.

What are the possible benefits and risks of participating?

There are no direct benefits involved with participating in this study. There is a small risk of pain, bruising or infection when blood samples are taken.

Where is the study run from?
Aintree University Hospital NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
June 2014 to February 2019

Who is funding the study?
Novartis Pharma AG (UK)

Who is the main contact?
Prof. Robert Moots
r.moots@liverpool.ac.uk

Contact information

Type(s)
Scientific

Contact name
Prof Robert Moots

Contact details
University of Liverpool
Clinical Sciences Centre
University Hospital Aintree
Longmoor Lane
Liverpool
United Kingdom
L9 7AL
+44 (0)151 529 5889
r.moots@liverpool.ac.uk

Additional identifiers

EudraCT/CTIS number
2015-004502-42

IRAS number

ClinicalTrials.gov number
NCT02854163

Secondary identifying numbers
30782

Study information

Scientific Title

SATURN: An exploration of the dynamic interaction between IL-17, IL-17 inhibition with (secukinumab) and neutrophils in psoriatic arthritis in vitro and ex vivo with exploratory study on the potential role of Vitamin D

Acronym

SATURN

Study objectives

The aim of this study is to investigate, in detail, the clinical and molecular effects of IL-17 and inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo. In addition, the secondary and exploratory aims are to explore the potential relationship between vitamin D on neutrophil function and response to IL-17 inhibition in psoriatic arthritis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North West - Liverpool Central Research Ethics Committee, 10/02/2016, ref: 16/NW/0006

Study design

Interventional; Design type: Treatment, Drug, Immunotherapy

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Specialty: Musculoskeletal disorders, Primary sub-specialty: Inflammatory arthritis; UKCRC code/ Disease: Musculoskeletal/ Other disorders of the musculoskeletal system and connective tissue

Interventions

Interventions as of 23/05/2017:

Eligible patients with PsA are registered into the study.

Participants are treated with Secukinumab and receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months, in addition to standard disease-modifying anti-rheumatic drugs (DMARD) therapy

Participants are followed up a 3, 6, 9 and 12 months post treatment.

The healthy controls will be recruited from staff at the University of Liverpool or Aintree University hospitals and who are not taking nor have taken over the preceding 6 months, any immunosuppressive agent including systemic corticosteroids and whose health is otherwise good. There will be an equal balance of males to females. The healthy controls will provide one sample of blood for neutrophil studies (in vitro work). The effects of adding exogenous IL-17 and of inhibiting this cytokine by secukinumab, on highly-purified neutrophils isolated from the blood of 10 healthy controls, will be determined. Neutrophil survival will be recorded together with full details on priming of respiratory burst, expression of integrins and other opsono-receptors, apoptosis, phagocytosis and chemotaxis. Experiments will be repeated after neutrophil preparations have been "spiked" with contaminating PBMC's. If these experiments indicate that the effects of IL-17 on neutrophils are indirect, we will determine the mechanism of PBMC activation. For example, this will include measurement of IL-17 derived neutrophil activating cytokines (by ELISA or multiplex) and/or using blocking monoclonal antibodies.

Original interventions:

Patients with PsA are allocated to intervention and control arms in a 4:1 ratio by means of computer generated random permuted blocks of size 5. No stratification factors are included.

Control arm: Participants receive standard disease-modifying anti-rheumatic drugs (DMARD) therapy. This includes Methotrexate (5mg-25mg orally or subcutaneously) once a week, Sulphasalazine (500mg-1g orally) twice a day and Leflunomide (10mg-20mg orally) once a day for 12 months.

Intervention arm: Participants are treated with Secukinumab and receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months, in addition to standard DMARD therapy (as above).

Participants in both groups are followed up a 3, 6, 9 and 12 months post treatment.

The healthy controls will be recruited from staff at the University of Liverpool or Aintree University hospitals and who are not taking nor have taken over the preceding 6 months, any immunosuppressive agent including systemic corticosteroids and whose health is otherwise good. There will be an equal balance of males to females. The healthy controls will provide one sample of blood for neutrophil studies (in vitro work).

The effects of adding exogenous IL-17 and of inhibiting this cytokine by secukinumab, on highly-purified neutrophils isolated from the blood of 10 healthy controls, will be determined.

Neutrophil survival will be recorded together with full details on priming of respiratory burst, expression of integrins and other opsono-receptors, apoptosis, phagocytosis and chemotaxis. Experiments will be repeated after neutrophil preparations have been "spiked" with contaminating PBMC's. If these experiments indicate that the effects of IL-17 on neutrophils are indirect, we will determine the mechanism of PBMC activation. For example, this will include measurement of IL-17 derived neutrophil activating cytokines (by ELISA or multiplex) and/or using blocking monoclonal antibodies.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Secukinumab

Primary outcome measure

1. Neutrophil phenotype is measured by quantifying receptor expression (n=7) using flow cytometry assays at baseline, 3, 6 and 12 months post treatment
2. Neutrophil lifespan is measured by quantifying apoptosis using flow cytometry assays at baseline, 3, 6 and 12 months post treatment
3. Function and production of IL-17 in response to secukinumab is measured using ELISA assays at baseline, 3, 6 and 12 months post treatment on healthy controls

Secondary outcome measures

1. Vitamin D status is measured using routine blood test measuring the amount of Vitamin D at baseline, 3, 6 and 12 months post treatment
2. Vitamin D receptor is measured using flow cytometry assays at baseline, 3, 6 and 12 months post treatment
3. Clinical response is measured using ACR20, PASI75, PASI90 and NAPS1 measurements at baseline, 3, 6, 9 and 12 months post treatment
4. Quality of Life is measured using EQ5D and HAQ scores collected at baseline, 3, 6, 9 and 12 months post treatment
5. Toxicity is measured by the number and percent of patients with adverse event, serious adverse events, infections and serious infections, malignancies, acute injection site reactions and immunogenicity at baseline, 3, 6, 9 and 12 months post treatment

Overall study start date

01/06/2014

Completion date

28/02/2019

Eligibility

Key inclusion criteria

Inclusion criteria for healthy controls:

1. Not taking or have taken over the preceding 6 months any immunosuppressive agents including corticosteroid
2. Healthy
3. Able to give consent
4. Aged over 18 years

Inclusion criteria for Patients with PsA:

1. Active psoriatic arthritis (fulfilling CASPAR criteria) affecting ≥ 2 peripheral joints (swollen and tender) that have not responded to at least one standard DMARDs
2. All meet CASPAR criteria for diagnosis of PsA
3. Be rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) negative at screening
4. Have had no prior exposure to biologic therapy
5. Not have received parenteral glucocorticosteroids in the 6 weeks prior to the baseline assessment
6. If taking oral glucocorticoids remain on a stable dose of $<10\text{mg}$ throughout the study with no change in dose in the 6 weeks prior to baseline assessment,

- 7. If taking methotrexate or other DMARDs remain on a stable dose throughout the study and not have changed dose or therapy for 6 weeks prior to the baseline assessment
- 8. Able to give consent
- 9. Aged over 18 years

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 30; UK Sample Size: 30

Total final enrolment

19

Key exclusion criteria

Exclusion criteria for healthy controls:

Taking or have taken over the preceding 6 months any immunosuppressive agents including corticosteroid.

Exclusion criteria as of 23/05/2017:

Exclusion criteria for Patients with PsA:

1. Active or chronic infection including mycobacterium tuberculosis, HIV, hepatitis B or C , Hep B or C
2. Absence of active psoriatic arthritis
3. Patients who are starting anti-TNF therapy for treating PsA
4. Pregnancy and planning pregnancy
- 4.1. WOCBP who are unwilling or unable to use acceptable method to avoid pregnancy for study duration plus timeframe as specified in section 5.2.5.
- 4.2. Women who are pregnant or breastfeeding
- 4.3. Sexually active fertile men not using effective birth control if their partners are WOCBP.
5. Malignancy
6. Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process obtained within 3 months prior to Screening and evaluated by a qualified physician
7. Patients with hyponatraemia and nephrotic syndrome
8. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor
9. Use of any investigational drug and/or devices within 4 weeks before randomization registration or a period of 5 half-lives of the investigational drug, whichever is longer
10. Significant comorbidity that, in the opinion of the investigator, would impact on ability to participate
11. Any change in the dose of oral glucocorticosteroids or DMARDs in the prior 6 weeks prior to the Baseline visit or use of i.v. intramuscular or intra-articular glucocorticosteroid during the last

6 weeks prior to the enrollment visit

12. Patients who have previously been treated with TNF α inhibitors (investigational or approved)
13. History of hypersensitivity to the study drug or its excipients or to drugs of similar classes
14. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
15. Active ongoing inflammatory diseases other than PsA that might confound the evaluation of the benefit of secukinumab therapy
16. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions which in the opinion of the Investigator immunocompromise the patient and/or place the patient at unacceptable risk for participation in an immunomodulatory therapy
17. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension ($\geq 160/95$ mmHg), congestive heart failure (New York Heart Association status of class III or IV), uncontrolled diabetes
18. History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests (LFT) such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or serum bilirubin. The Investigator should be guided by the following criteria:
 - 18.1. Any single parameter may not exceed 2 x upper limit of normal (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to enrollment/randomization registration, to rule out laboratory error.
 - 18.2. If the total bilirubin concentration is increased above 2 x ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin. In any case, serum bilirubin should not exceed 1.6 mg/dL (27 μ mol/L)
19. History of renal trauma, glomerulonephritis, or patients with 1 kidney only, or a serum creatinine level exceeding 1.5 mg/dL (132.6 μ mol/L)
20. Screening total white blood cell (WBC) count $< 3\,000/\mu$ L, or platelets $< 100\,000/\mu$ L or neutrophils $< 1\,500/\mu$ L or hemoglobin < 8.5 g/dL (85 g/L)
21. Active systemic infections during the last 2 weeks (exception: common cold) prior to registration
22. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis according to local practice/guidelines) or a positive QuantiFERON TB-Gold test or TB-Spot Test (as indicated in Section 4.1 and Table 6-1). Patients with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active tuberculosis. If presence of latent tuberculosis is established then treatment according to local country guidelines must have been initiated
23. Known infection with human immunodeficiency virus, hepatitis B or hepatitis C at Screening or registration
24. History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed)
25. Use of Vitamin D containing supplements
26. Inability or unwillingness to undergo repeated venepuncture (e.g. because of poor tolerability or lack of access to veins)
27. Patients who have received a live vaccine within 4 weeks prior to planned registration must be excluded

Previous exclusion criteria:

Exclusion criteria for Patients with PsA:

1. Active or chronic infection including mycobacterium tuberculosis, HIV, hepatitis B or C , Hep B or C

2. Absence of active psoriatic arthritis
3. Patients who are starting anti-TNF therapy for treating PsA
4. Pregnancy or planning conception or pregnancy. The patient information sheet will state that "if you wish to become pregnant, you need to wait for a minimum of 20 weeks after receiving the last dose of the study medication."
5. Malignancy
6. Chest X-ray or chest MRI with evidence of ongoing infectious or malignant process obtained within 3 months prior to Screening and evaluated by a qualified physician
7. Previous exposure to secukinumab or other biologic drug directly targeting IL-17 or IL-17 receptor
8. Patients taking high-potency opioid analgesics (e.g. methadone, hydromorphone, morphine)
9. Use of any investigational drug and/or devices within 4 weeks before randomization or a period of 5 half-lives of the investigational drug, whichever is longer
10. Significant comorbidity that, in the opinion of the investigator, would impact on ability to participate
11. Any change in the dose of oral glucocorticosteroids or DMARDS in the prior 6 weeks prior to the Baseline visit or use of i.v. intramuscular or intra-articular glucocorticosteroid during the last 6 weeks prior to the enrollment visit
12. Patients who have previously been treated with TNF α inhibitors (investigational or approved)
13. History of hypersensitivity to the study drug or its excipients or to drugs of similar classes
14. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
15. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information
17. Active ongoing inflammatory diseases other than PsA that might confound the evaluation of the benefit of secukinumab therapy
18. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions which in the opinion of the Investigator immunocompromise the patient and/or place the patient at unacceptable risk for participation in an immunomodulatory therapy
19. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension ($\geq 160/95$ mmHg), congestive heart failure (New York Heart Association status of class III or IV), uncontrolled diabetes
20. History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests (LFT) such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or serum bilirubin. The Investigator should be guided by the following criteria:
 1. Any single parameter may not exceed 2 x upper limit of normal (ULN). A single parameter elevated up to and including 2 x ULN should be re-checked once more as soon as possible, and in all cases, at least prior to enrollment/randomization, to rule out laboratory error.
 2. If the total bilirubin concentration is increased above 2 x ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin. In any case, serum bilirubin should not exceed 1.6 mg/dL (27 μ mol/L)
21. History of renal trauma, glomerulonephritis, or patients with 1 kidney only, or a serum creatinine level exceeding 1.5 mg/dL (132.6 μ mol/L)
22. Screening total white blood cell (WBC) count $< 3\,000/\mu$ L, or platelets $< 100\,000/\mu$ L or neutrophils $< 1\,500/\mu$ L or hemoglobin < 8.5 g/dL (85 g/L)
23. Active systemic infections during the last 2 weeks (exception: common cold) prior to

randomization

24. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by either a positive purified protein derivative (PPD) skin test (the size of induration will be measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5 mm or according to local practice/guidelines) or a positive QuantiFERON TB-Gold test (as indicated in Section 6.5.4 and Table 6-1). Patients with a positive test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active tuberculosis. If presence of latent tuberculosis is established then treatment according to local country guidelines must have been initiated

25. Known infection with human immunodeficiency virus, hepatitis B or hepatitis C at Screening or randomization

26. Use of Vitamin D containing supplements

Date of first enrolment

14/10/2016

Date of final enrolment

14/10/2017

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Aintree University Hospital NHS Foundation Trust

Longmoor Lane

Liverpool

United Kingdom

L9 7AL

Sponsor information

Organisation

University of Liverpool

Sponsor details

The Foundation Building

765 Brownlow Hill

Liverpool

England

United Kingdom

L69 7ZX

Sponsor type

University/education

ROR

<https://ror.org/04xs57h96>

Funder(s)

Funder type

Industry

Funder Name

Novartis Pharma AG

Results and Publications

Publication and dissemination plan

The results will be analysed and published as soon as possible after the trial has been closed (after last patient recruited has attended his/her last trial visit).

Intention to publish date

31/12/2019

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository (Liverpool Clinical Trials Units' database)

IPD sharing plan summary

Stored in repository

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
HRA research summary			28/06/2023	No	No